HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Archive

All News

Every briefing, headline, and filing we've published, newest first.

PolicyAJMC ↗
Apr 29, 2026
Teva nabs experimental Tourette drug in $700M Emalex buyout
DealsBioPharma Dive ↗
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes se…
Apr 29, 2026
Chiesi Buys KalVista for $1.9B, Adding an Approved Drug and Commercial Unit
DealsBriefing
Chiesi has announced a $1.9B acquisition of KalVista Pharmaceuticals, continuing 2026’s brisk deal pace among …
Apr 29, 2026
Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?
PipelinePharmaVoice ↗
Results show a landmark change that could double survival rates in one of the most difficult oncology diagnose…
Apr 29, 2026
FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board
PolicyFierceBiotech ↗
The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in …
Apr 29, 2026
Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts
PolicyFiercePharma ↗
Eleventh-hour settlements with two of the three generic drugmakers involved could bode well for both Pfizer an…
Apr 29, 2026
Lilly Extends Oncology Buying Spree with $2.3B Ajax Therapeutics Acquisition
DealsBriefing
Lilly’s $2.3 billion move for Ajax Therapeutics centers on a Type II JAK2 inhibitor it helped incubate, aiming…
Apr 29, 2026
PolicyAJMC ↗
Apr 28, 2026
The crown for healthcare admin tech is still up for grabs
The WeekEndpoints News ↗
A few years in, admin tech is still reigning as the king of health tech funding. Startups using AI to tackle m…
Apr 28, 2026
Hikma and Amarin's generic drug case heads to Supreme Court arguments
PolicyEndpoints News ↗
When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the …
Apr 28, 2026
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
PipelineBioPharma Dive ↗
Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed sign…
Apr 28, 2026
PolicySTAT News ↗
The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny label…
Apr 28, 2026
Why AI maker Anthropic’s deal with Coefficient Bio could be a pharma turning point
DealsPharmaVoice ↗
The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is ap…
Apr 28, 2026
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
DealsFiercePharma ↗
Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its ac…
Apr 28, 2026
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi,’ spurring big blockbuster forecasts
PipelineFierceBiotech ↗
Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a…
Apr 28, 2026
Intellia’s Lonvo-z Becomes First In Vivo CRISPR Therapy to Reach FDA Doorstep
PipelineBriefing
Intellia’s hereditary angioedema therapy cut swelling attacks by 87% in phase 3, positioning the biotech for t…
Apr 28, 2026
Supreme Court grapples with multibillion-dollar wave of lawsuits over Roundup cancer claims
PolicySTAT News ↗
The Supreme Court seemed divided Monday over whether to block thousands of lawsuits alleging the maker of the …
Apr 27, 2026
Veradermics wins at growing hair with oral Rogaine in first key test as a public company
PipelineEndpoints News ↗
Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral…
Apr 27, 2026
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
DealsFiercePharma ↗
Merck & Co.’s $1 billion deal with Google Cloud is seeking to bolster its AI credentials—and the U.S. Big …
Apr 27, 2026
McKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B
DealsFierceBiotech ↗
McKesson has let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo…
Apr 27, 2026
Roche Sits Out $29B Pharma Buying Frenzy, Citing Debt and Discipline
Money
As peers spent $29B in late-March M&A, Roche CEO Thomas Schinecker said high rates, no patent cliffs, and 19 d…
Apr 27, 2026
Sun Pharma to buy Organon for $11.75B in major portfolio expansion
DealsEndpoints News ↗
Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosi…
Apr 27, 2026
Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push
PolicyFierceBiotech ↗
The FDA is awarding national priority vouchers to Compass Pathways, Usona Institute and Transcend Therapeutics…
Apr 26, 2026
Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval
PipelineFiercePharma ↗
After a series of setbacks for Sanofi’s tolebrutinib, the French company has scored a victory for the multiple…
Apr 26, 2026
← Newer Page 10 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.